The burden of migraine in the United States: Current and emerging perspectives on disease management and economic analysis

Value in Health

Volumn 12, Issue 1, 2009, Pages 55-64

  Hazard, Elisabeth ^a   Munakata, Julie ^a   Bigal, Marcelo E ^b,c   Rupnow, Marcia F T ^d   Lipton, Richard B ^b,c  

^a IMS Consulting   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Burden of illness; Economic; Migraine; United States

Indexed keywords

TRIPTAN DERIVATIVE;

ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; ECONOMIC ASPECT; FEMALE; HUMAN; INCIDENCE; MALE; MEDICAL LITERATURE; MIGRAINE; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COST OF ILLNESS; EFFICIENCY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; QUALITY OF LIFE; UNITED STATES; YOUNG ADULT;

EID: 58849162823     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00404.x     Document Type: Article

References (79)

1. Bigal ME, Kolodner KB, Lafata JE, et al. Patterns of medical diagnosis and treatment of migraine and probable migraine in a health plan. Cephalalgia 2006 26 : 43 9.
2. Kolodner K, Lipton RB, Lafata JE, et al. Pharmacy and medical claims data identified migraine sufferers with high specificity but modest sensitivity. J Clin Epidemiol 2004 57 : 962 72.
3. Patel NV, Bigal ME, Kolodner KB, et al. Prevalence and impact of migraine and probable migraine in a health plan. Neurology 2004 63 : 1432 8.
4. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007 27 : 193 210.
5. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost because of common pain conditions in the US workforce. JAMA 2003 290 : 2443 54.
6. Solomon GD, Price KL. Burden of migraine. A review of its socioeconomic impact. Pharmacoeconomics 1997 11 (Suppl. 1 S1 10.
7. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999 159 : 813 8.
8. Lipton RB, Pan J. Is migraine a progressive brain disease? JAMA 2004 291 : 493 4.
9. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003 106 : 81 9.
10. Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology 1994 44 (6 Suppl. 4 S24 39.
11. Feczko JM. Cost of sumatriptan. Lancet 1992 340 : 243.
12. Kozma CM, Mauch RP, Reeder CE, Lawrence BJ. A literature review comparing the economic, clinical, and humanistic attributes of dihydroergotamine and sumatriptan. Clin Ther 1994 16 : 1037 51.
13. Rozen TD, Swanson JW, Stang PE, et al. Increasing incidence of medically recognized migraine headache in a United States population. Neurology 1999 53 : 1468 73.
14. Rozen TD, Swanson JW, Stang PE, et al. Incidence of medically recognized migraine: a 1989-1990 study in Olmsted County, Minnesota. Headache 2000 40 : 216 23.
15. Stewart WF, Lipton RB. The economic and social impact of migraine. Eur Neurol 1994 34 (Suppl. 2 12 7.
16. Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache 1994 34 : 319 28.
17. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005 45 (Suppl. 1 S3 13.
18. Linet MS, Stewart WF, Celentano DD, et al. An epidemiologic study of headache among adolescents and young adults. JAMA 1989 261 : 2211 6.
19. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992 267 : 64 9.
20. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001 41 : 646 57.
21. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007 47 : 355 63.
22. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002 58 : 885 94.
23. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007 68 : 343 9.
24. Dodick DW, Lipsy RJ. Advances in migraine management: implications for managed care organizations. Manag Care 2004 13 : 45 51.
25. Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R. Incidence of primary headache: a Danish epidemiologic follow-up study. Am J Epidemiol 2005 161 : 1066 73.
26. Bille B. A 40-year follow-up of school children with migraine. Cephalalgia 1997 17 : 488 91.
27. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998 38 : 87 96.
28. Celentano DD, Stewart WF, Lipton RB, Reed ML. Medication use and disability among migraineurs: a national probability sample survey. Headache 1992 32 : 223 8.
29. Fitzpatrick RM, Hopkins A. Illness behavior and headache, and the sociology of consultations for headache. In : Hopkins A, ed., Headache-Problems in Diagnosis and Management. Philadelphia, PA : WB Saunders, 1988.
30. Turner-Bowker DM, Bayliss MS, Ware JE, et al. Usefulness of the SF-8 Health Survey for comparing the impact of migraine and other conditions. Qual Life Res 2003 12 : 1003 12.
31. Lipton RB, Hamelsky SW, Kolodner KB, et al. Migraine, quality of life, and depression: a population-based case-control study. Neurology 2000 55 : 629 35.
32. Freitag FG. The cycle of migraine: patients' quality of life during and between migraine attacks. Clin Ther 2007 29 : 939 49.
33. Osterhaus JT, Townsend RJ, Gandek B, et al. Measuring the functional status and well-being of patients with migraine headache. Headache 1994 34 : 337 43.
34. Pesa J, Lage MJ. The medical costs of migraine and comorbid anxiety and depression. Headache 2004 44 : 562 70.
35. Barron R, Carlsen J, Duff SB, Burk C. Estimating the cost of an emergency room visit for migraine attack. J Med Econ 2003 6 : 43 53.
36. Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002 42 : 501 9.
37. Elston LJ, Moon C, Leotta C, et al. The medical care utilization and costs associated with migraine headache. J Gen Intern Med 2004 19 : 1005 12.
38. Etemad LR, Yang W, Globe D, et al. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm 2005 11 : 137 44.
39. Hawkins K, Rupnow M, Wang S. Direct cost burden of migraine among members of US employers. Value Health 2006 9 : A85.
40. Gibbs TS, Fleischer AB Jr., Feldman SR, et al. Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache 2003 43 : 330 5.
41. Scher AI, Bigal ME, Lipton RB. Comorbidity of migraine. Curr Opin Neurol 2005 18 : 305 10.
42. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994 28 : 659 64.
43. Stang PE, Crown WH, Bizier R, et al. The family impact and costs of migraine. Am J Manag Care 2004 10 : 313 20.
44. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 1996 16 : 231 8.
45. Von KM, Stewart WF, Simon DJ, Lipton RB. Migraine and reduced work performance: a population-based diary study. Neurology 1998 50 : 1741 5.
46. Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med 1997 39 : 320 7.
47. Gerth WC, Carides GW, Dasbach EJ, et al. The multinational impact of migraine symptoms on healthcare utilisation and work loss. Pharmacoeconomics 2001 19 : 197 206.
48. Goetzel RZ, Long SR, Ozminkowski RJ, et al. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med 2004 46 : 398 412.
49. Hawkins K, Wang S, Rupnow MF. Indirect cost burden of migraine in the United States. J Occup Environ Med 2007 49 : 368 74.
50. Blanchard EB, Andrasik F, Appelbaum KA, et al. The efficacy and cost-effectiveness of minimal-therapist-contact, non-drug treatments of chronic migraine and tension headache. Headache 1985 25 : 214 20.
51. Richardson GM, McGrath PJ. Cognitive-behavioral therapy for migraine headaches: a minimal-therapist-contact approach versus a clinic-based approach. Headache 1989 29 : 352 7.
52. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992 2 : 67 76.
53. de Lissovoy G, Lazarus SS. The economic cost of migraine. Present state of knowledge. Neurology 1994 44 (Suppl. 4 S56 62.
54. Lipton RB, Stewart WF, Von KM. The burden of migraine. A review of cost to society. Pharmacoeconomics 1994 6 : 215 21.
55. Legg RF, Sclar DA, Nemec NL, et al. Cost-effectiveness of sumatriptan in a managed care population. Am J Manag Care 1997 3 : 117 22.
56. Biddle AK, Shih YC, Kwong WJ. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy 2000 20 : 1356 64.
57. Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 1998 55 : 889 922.
58. Belsey JD. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials. Curr Med Res Opin 2004 20 : 659 69.
59. Mannix LK, Adelman JU, Goldfarb SD, et al. Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms. Am J Manag Care 2002 8 (Suppl. 3 S94 101.
60. Reeder CE, Steadman S, Goldfarb SD. Economic comparison of oral triptans for management of acute migraine: implications for managed care. Am J Manag Care 2002 8 (Suppl. 3 S80 4.
61. Wang JT, Barr CE, Torigoe Y, et al. Cost savings in migraine associated with less chest pain on new triptan therapy. Am J Manag Care 2002 8 (Suppl. 3 S102 7.
62. Williams P, Reeder CE. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J Manag Care Pharm 2004 10 : 259 65.
63. Williams P, Reeder CE. Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. Clin Ther 2003 25 : 2903 19.
64. Perfetto EM, Weis KA, Mullins CD, et al. An economic evaluation of triptan products for migraine. Value Health 2005 8 : 647 55.
65. Zhang L, Hay JW. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine. CNS Drugs 2005 19 : 635 42.
66. Limmroth V, Katsarava Z, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002 59 : 1011 4.
67. Goldfarb SD, Duncan BS, Dans PE, Sloan AS. HMO direct costs and health care resources use after implementation of a monthly limit on sumatriptan. Am J Health Syst Pharm 1999 56 : 2206 10.
68. Hoffman L, Mayzell G, Pedan A, et al. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray. J Manag Care Pharm 2003 9 : 335 45.
69. Adelman JU, Von SR. Cost considerations in headache treatment. Part 1: prophylactic migraine treatment. Headache 1995 35 : 479 87.
70. Kaniecki R, Lucas S. Treatment of Primary Headache: Preventive Treatment of Migraine. Standards of Care for Headache Diagnosis and Treatment. Chicago, IL : National Headache Foundation, 2004.
71. Silberstein SD. Preventive treatment of headaches. Curr Opin Neurol 2005 18 : 289 92.
72. Adelman JU, Adelman LC, Von SR. Cost-effectiveness of antiepileptic drugs in migraine prophylaxis. Headache 2002 42 : 978 83.
73. Brown JS, Rupnow MF, Neumann P, et al. Cost effectiveness of topiramate in the prevention of migraines in the United States: an update. Manag Care Interface 2006 19 : 31 8.
74. Invited lectures. Cephalalgia 2004 24 : 772 4.
75. Loder E, Biondi D. General principles of migraine management: the changing role of prevention. Headache 2005 45 (Suppl. 1 S33 47.
76. Khalil NM, Legg NJ, Anderson DJ. Long term decline of P100 amplitude in migraine with aura. J Neurol Neurosurg Psychiatry 2000 69 : 507 11.
77. Kruit MC, van Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004 291 : 427 34.
78. Wingerchuk DM, Spencer B, Dodick DW, Demaerschalk BM. Migraine with aura is a risk factor for cardiovascular and cerebrovascular disease: a critically appraised topic. Neurologist 2007 13 : 231 3.
79. Tietjen EG. Migraine and ischaemic heart disease and stroke: potential mechanisms and treatment implications. Cephalalgia 2007 27 : 981 7.